Published in Women's Health Weekly, June 1st, 1998
Prognosis was the same for both groups, even though the BRCA-associated tumors were more likely to manifest aggressive features.
Researchers Mark E. Robson, MD, et al. at Memorial Sloan-Kettering Cancer Center in New York reviewed the clinical records of 91 Ashkenazi Jewish women who were diagnosed with breast cancer at or before age 42. They found that one-third of the women had a BRCA1 or BRCA2 mutation.
Though BRCA-associated tumors appeared more aggressive when examined...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly